Emmaus Life Sciences Reports Q2 2023 Financial Results

Provided By PR Newswire

Last update: Aug 14, 2023

Record Net Revenues Contributed to Income from Operations

Sixth Straight Quarterly Increase in Net Revenues

TORRANCE, Calif., Aug. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and six months ended June 30, 2023.